4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

10-Q - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

DEF 14A - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Recent Company Highlights Revenue of $5.4 million, which includes a reduction of $1.2 million for product recalled from France during the third quarter AI product revenue in the third quarter from the Virtual Care Suite (VCS) grew by 82% versus prior year as first patients in the United States treated with GLP-1s were on-boarded Last patient in AUDACITY FDA clinical trial successfully exited, putting top-line readout on track for the end of the year Work

19,428 patients treated with the Allurion Program across 72 countries lost an average of 12.2% of total body weight Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2024, the annual meeting of The Obesity Society. The first abstract comprises outcomes data from Allurion's largest real-world cohort on record. The data, gathered from 19,428 patients across 72 countries treated between 2018 and 2023 with the Allurion Program with results tracked digitally through the Allurion Virtual Care Suite, reveals consistent and significant weight loss outcomes with an average weight reduction of 12.2% at f

Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the conf

Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for the Allurion Balloon. The Company expects to file the fourth and final module of the PMA containing the clinical data from its AUDACITY trial early next year. "These submissions are a critical milestone for Allurion, and I commend our team for their efforts," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "We are pleased to capitalize on the opportunity that the FDA provides through its modular submission program to improve the efficiency of our applicatio

In a study of 167 patients, average weight reduction was 15.7% at four months, 17.1% at six months, and 14.7% at one year Body fat percentage decreased at six months with no change in muscle mass Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the publication of a study in the journal Clinical Obesity on the impact of the Allurion Program on weight reduction and body composition. The study evaluated weight loss and body composition changes for 167 patients with an average body mass index (BMI) of 31.3. After four months of balloon therapy, patients achieved an average weight reduction of 15.7%. Patients continued to lose weight after balloo

Systematic review of 11 studies involving 2,107 patients reports average weight reduction of 12.5% with significant improvements in metabolic health Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis reviewed studies conducted between 2016 and 2024 and included data from 11 observational studies comprising a total of 2,107 patients. The results of the meta-analysis demonstrated a mean weight reduction of 12.5% and significant reduction in body mass index (BMI) of 4.75 kg/m2 at four months. Importantly, the analy

Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced that it received written notice (the "Notice") from the New York Stock Exchange (the "NYSE") that it is not in compliance with the NYSE's continued listing standards because the average market capitalization of the Company was less than $50.0 million over the consecutive 30 trading-day period ended August 29, 2024 and the Company's last reported stockholders' equity as of August 29, 2024 was less than $50.0 million. The Notice does not result in the immediate delisting of the Company's common stock from the NYSE. In accordance with NYSE procedures, within 45 days f

In a study of 91 adolescents, average weight loss was 13.1% at four months with no serious adverse events Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents. In the study, 91 adolescents between 15 and 17 years-old with average body mass index (BMI) of 35.6 received the Allurion Balloon and the Allurion Program delivered by a multidisciplinary team, including a trained nutrition professional with adolescent experience. Average weight reduction was 13.1% four months after placement, with no serious adverse events or early device removals. Obesit

Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

Average weight reduction in 486 patients improved from 10.5% at four months to 13.7% at one year on the Allurion Program Separate studies with patients on GLP-1 therapy report significant weight re-gain after discontinuation of drug and lifestyle intervention program Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average weight reduction of 10.5% at four months on the Allurion Program, improving to 13.7% at one year. This data indicate that weight loss can not only be maintained by utilizing the Allurion Program, but it can also be increased by taking advantage of the Program's ongoing virtual g

Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of its newest board member and Audit Committee Chair, Milena Alberti-Perez, effective as of March 11, 2024. "Milena joins the Allurion board during an exciting time in the company's history and is a proven and dynamic leader, with deep experience as an operator and board member," said Dr. Shantanu Gaur, Allurion Founder and CEO. "Her perspective and guidance will be invaluable as Allurion furthers its mission to treat the one billion people around the world with obesity." Ms. Alberti-Perez previously served as Chief Financial Officer at Getty Images (NYSE:GETY) and CFO at Peng

Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Brendan Gibbons as its new Chief Legal Officer and corporate secretary. Brendan joins Allurion with nearly 20 years' experience as a chief legal and compliance officer at three separate public companies. Most recently, Brendan served as Executive Vice President and Chief Legal Officer at Acushnet Company, the parent company of Titleist and other golf brands and a global leader in product innovation, precision manufacturing, and performance. Prior to Acushnet, Brendan held similar roles at Wolverine Worldwide and Carter's, Inc. Before going in-house, Brendan worked at Ropes &

Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced the pricing of an underwritten public offering of 14,406,508 shares of its common stock, par value $0.0001 per share (the "Shares"), and warrants to purchase 14,406,508 Shares (the "Warrants" and, together with the Shares, the "Securities") at a public offering price of $1.20 per share, for total gross proceeds of $17.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.Jefferies and TD Cowen are acting as joint book-running managers and representatives of the underwriters for the offering. Roth Capital

Shares of Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) fell sharply during Friday's session after the company announced pricing of $6.0 million public offering. Kaival Brands priced its 3,921,500 unit offering at $15.3 per unit. Kaival Brands Innovations Group shares dipped 47% to $1.52 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers American Rebel Holdings, Inc. (NASDAQ:AREB) shares jumped 161% to $0.8048 after the company signed a Connecticut distribution agreement with Dichello Distributors. Sharecare, Inc. (NASDAQ:SHCR) jumped 74% to $1.35 after the company agreed to be acquired by Altaris affiliate for $1.43 per share in cash.

Allurion Technologies, Inc. (NYSE:ALUR) shares are trading higher Thursday as the company announced the publication of a new study showing patients on its Allurion Program experienced an average weight loss of 14% and an average lean mass gain of 5.6% over four months. What’s Going On: The study involved 571 patients across three obesity centers who reduced their weight from 97.9kg to 84.0kg on average. Their lean mass increased from 49.8kg to 52.6kg. Higher activity levels played a role, with patients walking more than 8,000 steps daily achieving higher weight loss and lean mass gains compared to less active patients. These results compare with previous studies on GLP-1 therapy, whic

Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro. Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22). Jabil shares dipped 7.8% to $116.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers MGO Global, Inc. (NA

Gainers Allurion Technologies (NYSE:ALUR) shares increased by 152.8% to $2.68 during Thursday's regular session. The company's market cap stands at $128.5 million. Zapp Electric Vehicles (NASDAQ:ZAPP) stock moved upwards by 114.7% to $2.92. The company's market cap stands at $9.1 million. MGO Global (NASDAQ:MGOL) stock moved upwards by 75.58% to $0.8. The market value of their outstanding shares is at $14.6 million. ToughBuilt Industries (NASDAQ:TBLT) shares moved upwards by 33.01% to $4.15. The market value of their outstanding shares is at $3.2 million. Lobo EV Technologies (NASDAQ:LOBO) stock increased by 22.5% to $2.45. The market value of their outstanding shares is at $20.0 millio

SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

SC 13G - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)